失眠患者迎来新一代创新药，但只有新药还不够

Core Insights - The launch of the new insomnia drug, Lemborexant (brand name: Dazai Ke), on e-commerce platforms in early August exceeded expectations, selling over 8,000 boxes on the first day [1] - Lemborexant is the first dual orexin receptor antagonist approved in China, marking a significant innovation in the insomnia treatment market after a decade without new drugs [1][3] - The drug is not classified as a controlled substance, allowing for easier access and fewer restrictions for patients [3] Company Performance - Lemborexant achieved a projected global sales figure of $370 million in 2024, leading its category [1] - The drug has received positive market feedback in over 20 countries, particularly in Japan, where it holds a 40% market share in the prescription sleep aid market [3] Market Demand - There is a high demand for effective insomnia treatments among patients, particularly those suffering from chronic sleep issues due to work-related stress [3][9] - The company recognizes the need for better management of sleep disorders and aims to improve accessibility and treatment standardization for insomnia patients [3][14] Regulatory and Clinical Considerations - Lemborexant's mechanism of action allows for a more natural sleep induction with fewer side effects, distinguishing it from traditional sedative medications [3][10] - The company emphasizes the importance of proper medication use and gradual transition from older medications to avoid withdrawal symptoms [12][13] Future Directions - The company plans to focus on sleep health as a key business area, with ongoing research for new drugs targeting sleep-related issues [17] - There are efforts to push for Lemborexant's inclusion in health insurance to reduce patient costs and expand market access [18]